Abuaku, B., Duah, N., Quaye, L., Quashie, N., Malm, K., & Plange, C. B. (2016). Therapeutic efficacy of artesunate ‑ amodiaquine and artemether ‑ lumefantrine combinations in the treatment of uncomplicated malaria in two ecological zones in Ghana. Malaria Journal, 4–11. https://doi.org/10.1186/s12936-015-1080-x
Bopp, S., Magistrado, P., Wong, W., Schaffner, S. F., Mukherjee, A., Lim, P., … Volkman, S. K. (2018). Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-04104-z
Cavaco, I., Stromberg-Norklit, J., Kaneko, A., Msellem, M. I., Dahoma, M., Ribeiro, V. L., … Gil, J. P. (2005). CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. 2, 15–18. https://doi.org/10.1007/s00228-004-0871-8
Chen, N., Chavchich, M., Peters, J. M., Kyle, D. E., Gatton, M. L., & Cheng, Q. (2010). Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro. Antimicrobial Agents and Chemotherapy, 54(8), 3395–3401. https://doi.org/10.1128/AAC.01421-09
Duah, N. O., Matrevi, S. A., De Souza, D. K., Binnah, D. D., Tamakloe, M. M., Opoku, V. S., … Koram, K. A. (2013). Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy. Malaria Journal, 11, 135. https://doi.org/10.1186/1475-2875-11-135
Ferreira, P. E., Holmgren, G., Veiga, M. I., Uhlén, P., Kaneko, A., & Gil, J. P. (2011). PfMDR1: Mechanisms of transport modulation by functional polymorphisms. PLoS ONE, 6(9), 3–10. https://doi.org/10.1371/journal.pone.0023875
Hodel, E. M., Ley, S. D., Qi, W., Ariey, F., Genton, B., & Beck, H. (2009). A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs. 9, 1–9. https://doi.org/10.1186/1475-2875-8-285
Holmgren, G., Hamrin, J., Svärd, J., Mårtensson, A., Gil, J. P., & Björkman, A. (2007). Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infection, Genetics and Evolution, 7(5), 562–569. https://doi.org/10.1016/j.meegid.2007.03.005
Ingelman-Sundberg, M., & Rodriguez-Antona, C. (2005). Pharmacogenetics of drug-metabolizing enzymes: Implications for a safer and more effective drug therapy. Philosophical Transactions of the Royal Society B: Biological Sciences, 360(1460), 1563–1570. https://doi.org/10.1098/rstb.2005.1685
Kebamo, S., Tesema, S., & Geleta, B. (2015). Journal of Drug Metabolism and The Role of Biotransformation in Drug Discovery and Development. 6(5). https://doi.org/10.4172/2157-7609.1000196
Kiaco, K., Rodrigues, A. S., Rosário, V., Gil, J. P., & Lopes, D. (2017). The drug transporter ABCB1 c . 3435C > T SNP influences artemether – lumefantrine treatment outcome. Malaria Journal, 1–6. https://doi.org/10.1186/s12936-017-2006-6
Kudzi, W., Dodoo, A. N. O., & Mills, J. J. (2009). Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Medical Genetics, 10, 8–13. https://doi.org/10.1186/1471-2350-10-124
Kudzi, W., Dodoo, A. N. O., & Mills, J. J. (2010). Genetic polymorphisms in MDR1 , CYP3A4 and CYP3A5 genes in a Ghanaian population : a plausible explanation for altered metabolism of ivermectin in humans ?
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2012). Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews, 64(SUPPL.), 256–269. https://doi.org/10.1016/j.addr.2012.09.017
Lee, T. M. N., Huang, L., Johnson, M. K., Lizak, P., Kroetz, D., Aweeka, F., & Parikh, S. (2012). In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica, 42(11), 1088–1095. https://doi.org/10.3109/00498254.2012.693972
Lef??vre, G., & Thomsen, M. S. (1999). Clinical Pharmacokinetics of Artemether and Lumefantrine (Riamet??). Clinical Drug Investigation, 18(6), 467–480. https://doi.org/10.2165/00044011-199918060-00006
Li, X.-Q., Björkman, A., Andersson, T. B., Ridderström, M., & Masimirembwa, C. M. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. The Journal of Pharmacology and Experimental Therapeutics, 300(2), 399–407. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11805197
Lorenz T. C. (2012). Polymerase chain reaction: basic protocol plus troubleshooting and optimization strategies. Journal of visualized experiments : JoVE, (63), e3998. https://doi.org/10.3791/3998
Ministry of Health. (2009). Antimalarial Drug Policy for Ghana.
Mutagonda, R. F., Kamuhabwa, A. A. R., Minzi, O. M. S., Massawe, S. N., Asghar, M., Homann, M. V., … Aklillu, E. (2017). Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malaria Journal, 16(1), 1–10. https://doi.org/10.1186/s12936-017-1914-9
Ouji, M., Augereau, J.-M., Paloque, L., & Benoit-Vical, F. (2018). Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination . Parasite, 25, 24. https://doi.org/10.1051/parasite/2018021
Parikh, S., Ouedraogo, J. B., Goldstein, J. A., Rosenthal, P. J., & Kroetz, D. L. (2007). Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications for malaria treatment in Africa. Clinical Pharmacology and Therapeutics, 82(2), 197–203. https://doi.org/10.1038/sj.clpt.6100122
Sá, J. M., Twu, O., Hayton, K., Reyes, S., Fay, M. P., Ringwald, P., & Wellems, T. E. (2009). Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine . Proceedings of the National Academy of Sciences, 106(45), 18883–18889. https://doi.org/10.1073/pnas.0911317106
Sisowath, C., Ferreira, P. E., Bustamante, L. Y., Dahlström, S., Mårtensson, A., Björkman, A., … Gil, J. P. (2007). The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Tropical Medicine and International Health, 12(6), 736–742. https://doi.org/10.1111/j.1365-3156.2007.01843.x
Vinayak, S., Alam, T., Sem, R., Shah, N. K., Susanti, A. I., Lim, P., … Udhayakumar, V. (2010). Multiple Genetic Backgrounds of the Amplified Plasmodium falciparum Multidrug Resistance (pfmdr1) Gene and Selective Sweep of 184F Mutation in Cambodia. J Infect Dis., 201(10), 1551–1560. https://doi.org/10.1086/651949
White, N. J., & Nosten, F. (2007). Artemisinin-Based Combination Treatment of Falciparum Malaria. The American Journal of Tropical Medicine and Hygiene, 77(6_Suppl), 181–192. https://doi.org/10.4269/ajtmh.2007.77.181
Wigginton JE, Cutler DJ, Abecasis GR (2005). A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet, 76(5):887-93. doi: 10.1086/429864.
World Health Organization. (2014). World malaria report 2014. Retrieved April 23, 2019, from https://www.who.int/malaria/publications/world_malaria_report_2014/wmr-2014-no-profiles.pdf
World Health Organization. (2018). World Malaria Report 2018 Isbn 978 92 4 156565 3. Retrieved from www.who.int/malaria
Wu, A. H. B. (2011). Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clinical Proteomics, 8(1), 1–9. https://doi.org/10.1186/1559-0275-8-12
Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and Therapeutics, 138(1), 103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007